Plasma levels of citalopram enantiomers and metabolites in elderly patients

Psychopharmacology Bulletin

Volumn 33, Issue 1, 1997, Pages 109-112

  Foglia, John P ^a   Pollock, Bruce G ^b   Kirshner, Margaret A ^b   Rosen, Jules ^b   Sweet, Robert ^b   Mulsant, Benoit ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

chirality; citalopram; cytochrome P450; enantiomers

Indexed keywords

CITALOPRAM; DRUG METABOLITE; NORCITALOPRAM;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMENTIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; STEREOCHEMISTRY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOTRANSFORMATION; CITALOPRAM; FEMALE; HUMANS; MALE; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM;

EID: 0030941088     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Caldwell, J. The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol. 32:925-929, 1992.
2. Campbell, DB. Stereoselectivity in clinical pharmacokinetics and drug development. Eur. J. Drug Metab. Pharmacokinet. 15:109-125, 1990.
3. Chandler, MHH; Scott, SR; and Blouin, RA. Age-associated stereoselective alterations in hexobarbital metabolism. Clin. Pharmacol. Ther. 43:436-441, 1988.
4. Echizen, H; Vogelgesang, B; and Eichelbaum, M. Effects of d,1-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin. Pharmacol. Ther. 38:71-76, 1985.
5. Evans, AM; Nation, RL; Sansom, LN; Bochner, F; and Somogyi, AA. Stereoselective drug disposition: Potential for misinterpretation of drug disposition data. Br. J. Clin. Pharmacol. 26:771-780, 1988.
6. Gibaldi, M. Stereoselective and isozyme-selective drug interactions. Chirality 5:407-413, 1993.
7. Hyttel, J; Bogeso, KP; Perregaard, J; and Sanchez, C. The pharmacological effect of citalopram resides in S(+) enantiomer. J. Neural Transm. (Gen. Sect.) 88:157-160, 1992.
8. Kragh-Sorensen, P; Overo, KF; Pedersen, OL; Jensen, K; and Parnas, W. The kinetics of citalopram: Single and multiple dose studies in man. Acta Pharmacol. Toxicol. 48:53-60, 1981.
9. Lee, EJD, and Williams, KM. Chirality: Clinical pharmacokinetic and pharmacodynamic considerations. Clin. Pharmacokinet. 18:339-345, 1990.
10. Levin, HS; High, WM; Goethe, KE; Sisson, RA; Overall, JE; Rhoades, HM; Eisenberg, HM; Kalisky, Z; and Gary, HE. The Neurobehavioral Rating Scale: Assessment of the behavioral sequelae of head injury by the clinician. J. Neurol. Neurosurg. Psychiatry 50:183-193, 1987.
11. Lingjaerde, O; Ahlfors, UG; Bech, P; Dencker, SJ; and Elgen, K. The UKU Side Effect Rating Scale. Acta Psychiatr. Scand. 334(Suppl.):1-100, 1987.
12. Nation, RL. Chirality in new drug development: Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 27(4);249-255, 1994.
13. Overo, KF. Kinetics of citalopram in man; plasma levels in patients. Prog. Neuro-Pharmacol. Biol. Psychiatry 6:311-318, 1982.
14. Pollock, BG; Mulsant, B; Sweet, R; Burgio, L; Kirshner, M; Shuster, K; and Rosen, J. An open pilot study of citalopram for behavioral disturbances of dementia. Am. J. Geriatric Psychiatry 5(1)70-78, 1997.
15. Pollock, BG; Perel, JM; Altieri, L; Kirshner, M; Yeager, A; Houck, P; and Reynolds, CF. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol. Bull. 28(2):163-168, 1992.
16. Rochat, B; Amey, M; and Baumann, P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther. Drug Monit. 17:273-279, 1995.